Cogent Biosciences, Inc. Common Stock
Veridion Score
Composite trend over time
Why is COGT moving today?
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for COGT.
COGT insider activity
Cogent Biosciences, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Mixed: Not disclosed across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
The current Form 4 feed did not return value-bearing open-market rows for COGT.
COGT contract awards, year to date.
Public federal awards linked to this ticker.
COGT lobbying filings, year to date.
Registered lobbying filings matched to Cogent Biosciences, Inc. Common Stock.